SPIRONOLACTONE tablet

দেশ: মার্কিন যুক্তরাষ্ট্র

ভাষা: ইংরেজি

সূত্র: NLM (National Library of Medicine)

সক্রিয় উপাদান:

Spironolactone (UNII: 27O7W4T232) (Spironolactone - UNII:27O7W4T232)

থেকে পাওয়া:

AvPAK

INN (আন্তর্জাতিক নাম):

Spironolactone

রচনা:

Spironolactone 25 mg

প্রেসক্রিপশন টাইপ:

PRESCRIPTION DRUG

অনুমোদন অবস্থা:

Abbreviated New Drug Application

পণ্য বৈশিষ্ট্য

SPIRONOLACTONE - SPIRONOLACTONE TABLET
AVPAK
----------
SPIRONOLACTONE TABLETS, USP
WARNING
Spironolactone has been shown to be a tumorigen in chronic toxicity
studies in rats (see
PRECAUTIONS). Spironolactone should be used only in those conditions
described under
INDICATIONS AND USAGE. Unnecessary use of this drug should be avoided.
DESCRIPTION
Spironolactone tablets USP, for oral administration contain 25 mg, 50
mg, or 100 mg of the aldosterone
antagonist spironolactone, 17-hydroxy-7α - mercapto-3-oxo-17α
-pregn-4-ene-21-carboxylic acid γ-
lactone acetate. The molecular formula is C
H 0 S and is represented by the following structural
formula:
Spironolactone is practically insoluble in water, soluble in alcohol,
and freely soluble in benzene and in
chloroform. Inactive ingredients include calcium sulfate, corn starch,
crospovidone, dextrose,
hypromellose, magnesium stearate, maltodextrin, natural peppermint
flavor, polydextrose, polyethylene
glycol, povidone, silicon dioxide, titanium dioxide, triacetin.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Spironolactone is a specific pharmacologic antagonist of aldosterone,
acting primarily through
competitive binding of receptors at the aldosterone-dependent
sodium-potassium exchange site in the
distal convoluted renal tubule. Spironolactone causes increased
amounts of sodium and water to be
excreted, while potassium is retained. Spironolactone acts both as a
diuretic and as an antihypertensive
drug by this mechanism. It may be given alone or with other diuretic
agents which act more proximally
in the renal tubule.
ALDOSTERONE ANTAGONIST ACTIVITY
Increased levels of the mineralocorticoid, aldosterone, are present in
primary and secondary
hyperaldosteronism. Edematous states in which secondary aldosteronism
is usually involved include
congestive heart failure, hepatic cirrhosis, and the nephrotic
syndrome. By competing with aldosterone
for receptor sites, spironolactone provides effective therapy for the
edema and ascites in those
conditions. Spironolactone counterac